Serina Therapeutics (SER) Equity Average (2018 - 2025)
Historic Equity Average for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to $1.8 million.
- Serina Therapeutics' Equity Average rose 11178.65% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 11178.65%. This contributed to the annual value of -$15.8 million for FY2024, which is 3619.5% up from last year.
- Serina Therapeutics' Equity Average amounted to $1.8 million in Q3 2025, which was up 11178.65% from $1.8 million recorded in Q2 2025.
- In the past 5 years, Serina Therapeutics' Equity Average ranged from a high of $1.8 million in Q3 2025 and a low of -$30.0 million during Q4 2023
- For the 5-year period, Serina Therapeutics' Equity Average averaged around -$12.0 million, with its median value being -$11.7 million (2022).
- In the last 5 years, Serina Therapeutics' Equity Average crashed by 71230.03% in 2021 and then skyrocketed by 11692.11% in 2025.
- Serina Therapeutics' Equity Average (Quarter) stood at -$10.9 million in 2021, then crashed by 48.56% to -$16.2 million in 2022, then plummeted by 84.63% to -$30.0 million in 2023, then skyrocketed by 78.0% to -$6.6 million in 2024, then surged by 127.01% to $1.8 million in 2025.
- Its Equity Average stands at $1.8 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.2 million for Q1 2025.